Monte Rosa Therapeutics, Inc.
NASDAQ:GLUEBiotechnology
-$0.26 today
- Market cap
- $775.03M
- Beta
- 1.60
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.98
Volume 1.26M
Average 1.02M
GLUE Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Monte Rosa Therapeutics, Inc.NASDAQ: GLUE
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns positive
Q1 FY2026 accounts receivables was $6.99M, compared with -$1.24M a year earlier. Trailing-twelve-month accounts receivables was $1.23M. Over 3 fiscal years it compounded at +3245.2% a year.
Context
- Accounts receivables amounted to 5.7% of revenue in FY2025, up 5.2 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near $6.99M or moves back toward the trailing-twelve-month quarterly average of $306.5K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (7M) USD
- Year-over-year change
- -2208.4%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (7M) | -2208.4% |
| FY2024 | 2024-12-31 | 332K | -82.5% |
| FY2023 | 2023-12-31 | 1.9M | +1014538.5% |
| FY2022 | 2022-12-31 | (187) | — |
| FY2021 | 2021-12-31 | 0 | — |
Accounts Receivables vs competitors
How GLUE compares with its peers on the latest reported figures
- GLUE's LTM Mar 2026 accounts receivables of $1.23M is the 3rd largest of the 4 companies compared; the peer median is $2M.
- Its year-over-year change of +237.3% is the 2nd highest of 3, against a peer median of +123.1%.
- Accounts receivables amounts to 2.9% of revenue for GLUE, versus a peer median of 2.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $5.15M | -7.6% | -45.1% | 14.8% | |
| LTM Mar 2026 | $2M | +253.8% | -19.5% | 2.2% | |
| LTM Mar 2026 | $1.23M | +237.3% | +3245.2% | 2.9% | |
| LTM Aug 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding GLUE) | $2M | +123.1% | -32.3% | 2.2% | |
Competitors are the stored peer set for GLUE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (73.96M) | (108.5M) | (135.35M) | (72.7M) | (38.63M) |
| Depreciation & Amortization | 2.13M | 3.75M | 6.22M | 8.12M | 8.36M |
| Deferred Income Tax | 17K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.2M | 11.66M | 16.67M | 18.13M | 18.87M |
| Change in Working Capital | 6.29M | (2.13M) | 72.47M | 91.4M | (9.19M) |
| Accounts Receivables | 0 | (187) | 1.9M | 332K | (7M) |
| Inventory | 0 | 187 | 0 | 0 | 0 |
| Accounts Payables | (706K) | (744K) | 5.76M | 6.25M | (13.71M) |
| Other Working Capital | 6.99M | (1.39M) | 64.81M | 84.81M | 11.52M |
| Other Non-Cash Items | 960K | 2.76M | (3.81M) | (2.95M) | (2.2M) |
| Operating Cash Flow | (59.36M) | (92.47M) | (43.8M) | 42M | (22.8M) |
| Capital Expenditures | (9.73M) | (12.91M) | (19.04M) | (3.99M) | (4.7M) |
| Acquisitions (Net) | 79K | 109K | 62K | 0 | 0 |
| Purchases of Investments | 0 | (384.42M) | (103.15M) | (230.36M) | (376.68M) |
| Sales of Investments | 0 | 178M | 210.93M | 189.9M | 279.54M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (9.65M) | (219.22M) | 88.8M | (44.45M) | (101.83M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 237.75M | 20.06M | 27.49M | 944K | 30.35M |
| Common Stock Repurchased | 0 | 0 | 0 | (641K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.19M) | 411K | 0 | 98.59M | 0 |
| Financing Cash Flow | 377.56M | 20.47M | 27.49M | 98.89M | 30.35M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 308.55M | (291.22M) | 72.49M | 96.44M | (94.28M) |
| Free Cash Flow | (69.1M) | (105.38M) | (62.84M) | 38.01M | (27.5M) |
Monte Rosa Therapeutics, Inc.
NASDAQ:GLUE
Intrinsic Alpha fair value
Locked
Current Price
$9.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.